Please try another search
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
AddLife | 113.00 | 113.90 | 111.90 | -0.50 | -0.44% | 40.92K | 11:29:38 | ||
Arjo | 45.72 | 46.00 | 45.38 | -0.22 | -0.48% | 104.93K | 11:24:58 | ||
Bactiguard Holding AB | 70.00 | 72.80 | 70.00 | -2.80 | -3.85% | 2.41K | 11:29:33 | ||
BICO Group | 44.10 | 45.54 | 44.10 | -0.44 | -0.99% | 63.38K | 11:29:52 | ||
Boule Diagnostics | 10.90 | 10.90 | 10.20 | +0.94 | +9.44% | 28.86K | 11:22:30 | ||
C-Rad | 45.70 | 46.00 | 45.40 | -0.30 | -0.65% | 21.52K | 11:29:52 | ||
CellaVision AB | 263.00 | 276.00 | 262.50 | -7.00 | -2.59% | 11.10K | 11:20:05 | ||
Elekta B | 84.80 | 87.35 | 84.55 | -0.20 | -0.24% | 621.20K | 11:24:47 | ||
Episurf Medical AB | 0.26 | 0.27 | 0.25 | 0.00 | -0.38% | 721.30K | 11:29:54 | ||
Getinge B | 186.1 | 188.1 | 185.4 | -1.9 | -0.98% | 264.89K | 11:24:58 | ||
Immunovia publ AB | 1.44 | 1.49 | 1.42 | -0.03 | -2.31% | 151.63K | 11:20:01 | ||
Ortivus A | 4.300 | 4.740 | 4.100 | -0.460 | -9.66% | 2.12K | 11:29:58 | ||
Ortivus B | 2.980 | 2.990 | 2.850 | -0.010 | -0.33% | 4.46K | 11:13:10 | ||
Q linea | 2.59 | 2.81 | 2.51 | -0.07 | -2.64% | 432.04K | 10:56:49 | ||
RaySearch Labs B | 146.40 | 149.00 | 144.20 | -1.20 | -0.81% | 38.97K | 11:24:56 | ||
Sectra | 231.40 | 235.60 | 226.00 | -1.00 | -0.43% | 73.73K | 11:29:50 | ||
Sedana Medical | 27.25 | 27.50 | 25.50 | +1.45 | +5.62% | 345.81K | 11:29:41 | ||
Senzime | 6.9900 | 7.0000 | 6.7300 | +0.1100 | +1.60% | 113.31K | 11:29:48 | ||
Vitrolife | 178.60 | 182.50 | 178.60 | -5.40 | -2.93% | 28.63K | 11:29:56 | ||
Xvivo Perfusion AB | 432.50 | 440.00 | 428.50 | -2.00 | -0.46% | 47.14K | 11:29:56 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review